Utility of pharmacogenetic testing to optimise antidepressant pharmacotherapy in youth: a narrative literature review.

Autor:	Roberts B; The Perron Institute for Neurological and Translational Science, Nedlands, WA, Australia.; School of Biological Sciences, University of Western Australia, Crawley, WA, Australia., Cooper Z; The Perron Institute for Neurological and Translational Science, Nedlands, WA, Australia., Lu S; School of Psychological Science, University of Western Australia, Crawley, WA, Australia., Stanley S; Division of Psychiatry, School of Medicine, University of Western Australia, Crawley, WA, Australia., Majda BT; School of Medicine, University of Notre Dame, Fremantle, WA, Australia., Collins KRL; Western Australian Department of Health, North Metropolitan Health Service, Perth, WA, Australia., Gilkes L; School of Medicine, University of Notre Dame, Fremantle, WA, Australia.; Divison of General Practice, School of Medicine, University of Western Australia, Crawley, WA, Australia., Rodger J; The Perron Institute for Neurological and Translational Science, Nedlands, WA, Australia.; School of Biological Sciences, University of Western Australia, Crawley, WA, Australia., Akkari PA; The Perron Institute for Neurological and Translational Science, Nedlands, WA, Australia.; School of Human Sciences, University of Western Australia, Crawley, WA, Australia.; Centre for Molecular Medicine and Innovative Therapeutics, Murdoch University, Murdoch, WA, Australia.; Division of Neurology, Duke University Medical Centre, Duke University, Durham, United States., Hood SD; Division of Psychiatry, School of Medicine, University of Western Australia, Crawley, WA, Australia.
Jazyk:	angličtina
Zdroj:	Frontiers in pharmacology [Front Pharmacol] 2023 Sep 19; Vol. 14, pp. 1267294. Date of Electronic Publication: 2023 Sep 19 (Print Publication: 2023).
DOI:	10.3389/fphar.2023.1267294
Abstrakt:	Pharmacogenetics (PGx) is the study and application of how interindividual differences in our genomes can influence drug responses. By evaluating individuals' genetic variability in genes related to drug metabolism, PGx testing has the capabilities to individualise primary care and build a safer drug prescription model than the current "one-size-fits-all" approach. In particular, the use of PGx testing in psychiatry has shown promising evidence in improving drug efficacy as well as reducing toxicity and adverse drug reactions. Despite randomised controlled trials demonstrating an evidence base for its use, there are still numerous barriers impeding its implementation. This review paper will discuss the management of mental health conditions with PGx-guided treatment with a strong focus on youth mental illness. PGx testing in clinical practice, the concerns for its implementation in youth psychiatry, and some of the barriers inhibiting its integration in clinical healthcare will also be discussed. Overall, this paper provides a comprehensive review of the current state of knowledge and application for PGx in psychiatry and summarises the capabilities of genetic information to personalising medicine for the treatment of mental ill-health in youth. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The authors declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision. (Copyright © 2023 Roberts, Cooper, Lu, Stanley, Majda, Collins, Gilkes, Rodger, Akkari and Hood.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu